Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council
- J Allergy Clin Immunol. 2021 Apr;147(4):1174-1190.e1. doi: 10.1016/j.jaci.2021.01.013.
- 1. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.
- 2. Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
- 3. Department of Dermatology, Innovaderm Research, Montreal, Quebec, Canada.
- 4. Department of Dermatology and Allergy, Christine Kühne-Center for Allergy Research and Education, University of Bonn, Bonn, Germany.
- 5. Department of Dermatology, Kyoto University School of Medicine, Kyoto, Japan.
- 6. Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
- 7. Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: [email protected].
Atopic Dermatitis (AD) is a common yet complex Skin Disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management. Herein, we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases, or therapeutic response, and current practice of biomarkers in AD. We found that chemokine C-C motif ligand 17/Thymus and activation-regulated chemokine, a chemoattractant of TH2 cells, has currently the greatest evidence for robust correlation with AD clinical severity, at both baseline and during therapy, by using the recommendations, assessment, development, and evaluation approach. Although the potential of biomarkers in AD is yet to be fully elucidated, due to the complexity of the disease, a comprehensive approach taking into account both clinical and reliable, AD-specific biomarker evaluations would further facilitate AD research and improve patient management.